Our Portfolio

The Alzheimer's Drug Discovery Foundation (ADDF) publishes all programs that we fund in our research portfolio. Funded research projects can be viewed by the year of funding or by program area, and can also be found by searching for an investigator or certain keywords. Please note that your search term(s) must contain at least four characters.

Additionally, please note that grant funding priorities at the ADDF change over time. The ADDF maintains strict confidentiality with all of our funded projects and cannot share additional information on projects without permission from the investigator(s).

The ADDF does not recommend one particular clinical trial or research program over another. The ADDF is not responsible for the accuracy of the information provided, the selection of research subjects (patients) or the conduct of the clinical trial, treatment IND/expanded access program or other research program.

SEARCH GRANTS

Your grant search has return( 574 ) results

Page 1 of 58

Toggle Program

- Year
- Grantee
- Organization
- Title
- Program Area
- Amount

Toggle
- 2018
- Chris Hulme, PhD
- University of Arizona
- Optimization of Selective DYRK1A Inhibitors as a Treatment for Alzheimer’s Disease
- Drug Discovery, Oxidative Stress
- $99,964
Duration: 06/01/2018 - 06/01/2019

Abstract:

This program builds upon pivotal data generated by Dr. Chris Hulme and his collaborator, Dr. Travis Dunckley, through support from the ADDF and its partner, the Harrington Discovery Institute. Dr. Dunkley was selected as an ADDF-Harrington Scholar in 2016 to develop drugs that target an overactive enzyme called DYRK1A in Alzheimer’s disease. Inhibiting DYRK1A reduces the accumulation of tau protein, which is a component of tangles and is associated with cognitive decline. With this funding, Dr. Hulme will synthesize and test DYKR1A inhibitors that have optimal drug-like properties to increase the chances for success in human clinical trials. The goal is to support final phases of preclinical testing and, eventually, move into clinical trials.

Toggle
- 2018
- Brent Stockwell, PhD
- The Trustees of Columbia University
- Evaluation and Development of Optimized PDI Modulators for Alzheimer’s Disease
- Drug Discovery, Oxidative Stress
- $120,000
Duration: 05/01/2018 - 05/01/2019

Abstract:

Dr. Stockwell and his team are pursuing a novel strategy to reduce the level of oxidative stress in brain cells, which contributes to the development and progression of Alzheimer’s disease. He is targeting a specific protein known to be a large source of oxidative stress, called PDI. PDI levels increase in the presence of large amounts of misfolded proteins, a hallmark of Alzheimer’s and other neurodegenerative diseases. Dr. Stockwell and his team have engineered the drug LOC14 to target PDI. In preclinical experiments, LOC14 protects brain cells from several neurodegenerative diseases, including Huntington’s. With this funding, the team will create and test improved versions of LOC14 and develop biomarkers that can be used in eventual clinical trials. Dr. Stockwell hopes to develop LOC14 into a first-in-class therapy for Alzheimer’s.

Toggle
- 2018
- Joe Menetski, PhD
- Foundation for the National Institutes of Health
- ADNI-3
- Neuroimaging
- $50,000
Duration: 04/30/2018 - 04/30/2023

Abstract:

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark study currently being conducted at 59 clinical sites in the United States and Canada. It is the NIH's largest public-private partnership on brain research. ADNI is designed to facilitate the use and evaluation of biomarkers in clinical trials for Alzheimer’s. ADNI3 began in 2016 and will continue through 2021. It seeks to identify the earliest changes in brain structure and function as people transition from normal cognitive aging to mild cognitive impairment and early Alzheimer’s disease. In addition to continuing to follow approximately 697 subjects from the first and second phases annually, ADNI3 will enroll approximately 371 new subjects, while collecting clinical, cognitive, MRI, amyloid PET, FDG PET, cerebrospinal fluid, and genetic and autopsy data. This funding supports those efforts as well as new measurements of brain tau PET on all subjects over the course of a few years. ADNI3 will also enhance its current clinical tests by adding computerized cognitive testing and a performance-based functional assessment and updating its genetics methodology.

Toggle
- 2018
- Meredith Upton, MLIS
- Foundation for the National Institutes of Health
- Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders
- Biochemical Biomarkers (Blood, CSF
- $100,000
Duration: 03/14/2018 - 03/14/2020

Abstract:

Few biomarkers exist for diagnosing and subtyping patients with neurodegenerative diseases and psychiatric disorders. Prior research has shown that biological markers of abnormal inflammation levels are found in patients with these disorders. The goal of this two-year Biomarkers Consortium project is to identify and validate inflammatory biomarkers in cerebral spinal fluid (CSF) and/or blood. This will aid in the diagnosis and categorization of patients with neurodegenerative diseases and mood disorders. And the information generated from these efforts will facilitate clinical trials of therapies targeting inflammation.

Toggle
- 2018
- Kristine Yaffe, MD
- University of California, San Francisco
- Connection Between Depressive Symptoms and Dementia: When Best to Intervene
- Prevention, Clinical
- $100,000
Duration: 06/01/2018 - 06/01/2020

Abstract:

Many studies have reported that depression is linked to cognitive decline and dementia. However, it is currently unknown whether the timing of depression (e.g., early adulthood, midlife, or later-life) or the timing of treatment affects dementia risk. And there is evidence that antidepressants may reduce markers of Alzheimer’s disease, but it is not clear whether they lower dementia risk. With this funding, Dr. Yaffe will pool data from 4 cohorts of people ages 18 to 90+ in order to understand the relationships between depression, depressive symptoms, and the effects of antidepressants on cognitive decline and dementia risk. She will examine several classes of antidepressants including selective serotonin reuptake inhibitors (SSRIs). Findings from this study will identify which antidepressant treatment, if any, are useful in lowering dementia risk.

Toggle
- 2018
- Alison Drone
- Foundation for the National Institutes of Health
- Alzheimer’s Disease Research Summit 2018 Sponsorship
- Conferences, Other
- $5,000
Duration: 03/01/2018 - 03/02/2018

Abstract:

The ADDF is a proud sponsor of the 2018 Alzheimer’s Disease Summit. It is organized by the National Institutes of Health (NIH) with the goal to continue the development of a multi-disciplinary research agenda to accelerate the discovery and delivery of effective treatments for Alzheimer’s patients. More than 500 leaders from academia, industry, nonprofit organizations, and the federal government attend. The Summits are held every three

Toggle
- 2018
- Steven Finkbeiner, MD, PhD
- The J. David Gladstone Institutes
- Novel Human FTLD Neuron and Microglia Cell Models for Drug Discovery
- Drug Discovery, TDP-43
- $150,000
Duration: 02/01/2018 - 01/31/2019

Abstract:

Mutations in the progranulin gene are one of the most common causes of frontotemporal degeneration (FTD), a rare type of dementia. These mutations reduce levels of functional progranulin protein, which increases inflammation in the brain and can result in cell death. The FTD field lacks robust cellular platforms that represent human disease biology for drug discovery research. Dr. Finkbeiner plans to create human cell models to mimic the complex biology observed in patients with progranulin mutations. With this funding, he will generate neurons and microglia (the brain's immune cells) using skin cells from FTD patients with progranulin mutations. He and his team will then use the cell models to help identify potential new drugs targeting progranulin mutations. This project is co-funded through the ADDF's partnership with the Association for Frontotemporal Degeneration, now in its 11th year.

Toggle
- 2018
- Eugenia Trushina, PhD
- Mayo Clinic Rochester
- Small Molecule Inhibitors of Mitochondrial Complex I for Treatment of Alzheimer's Disease
- Drug Discovery, Mitochondria
- $600,000
Duration: 01/11/2018 - 01/11/2019

Abstract:

Mitochondria are the energy powerhouses of cells. Abnormal mitochondrial function has been shown to contribute to the onset of Alzheimer's disease. Dr. Trushina is developing novel drugs to restore mitochondrial dysfunction in diseased neurons. With ADDF funding over the last several years, she has translated her basic research findings into a large-scale drug discovery project. Dr. Trushina will now work with Dr. Lars Knutsen, an experienced medicinal chemist, on the next stages of drug development. They plan to test novel optimized molecules that target mitochondrial dysfunction for potential as effective Alzheimer’s treatments. This will enable Dr. Trushina to move the most promising compounds forward toward the goal of initiating human clinical trials in the next two to three years.

Toggle
- 2018
- Barbara Borroni, MD
- University of Brescia
- Non-invasive Brain Stimulation to Restore Cortical Plasticity and Connectivity in Genetic and Sporad
- Clinical
- $90,000
Duration: 11/15/2017 - 11/14/2020

Abstract:

Dr. Borroni and her team discovered that people with a disease-causing mutation for frontotemporal degeneration (FTD) have impairment in specific brain circuits nearly two decades before the onset of symptoms. Non-invasive techniques such as transcranial direct current stimulation (tDCS) have been shown to modulate brain circuits in healthy subjects and improve cognitive function in patients with neurodegenerative disorders. With this award, Dr. Borroni will conduct a clinical trial to explore the effects of repeated sessions of tDCS in patients with FTD and in presymptomatic carriers with a genetic mutation for FTD, who already show impairment in brain circuit functioning. This is the first ever trial to test a non-pharmacological approach to FTD. This award was made through The Fund to Treat FTD, in collaboration with the Association for Frontotemporal Degeneration.

Toggle
- 2018
- Roberta Diaz Brinton, PhD
- University of Arizona
- Allopregnanolone Novel Patentable Formulations to Advance Commercialization
- Clinical
- $150,000
Duration: 11/01/2017 - 12/31/2018

Abstract:

Dr. Brinton is currently preparing for a phase 2 clinical trial of allopregnanolone, which is on track to become the first neuroregenerative therapy for Alzheimer’s disease. Allopregnanolone is a naturally occurring neuro-steroid that spurs a process called neurogenesis, which involves regenerating lost neurons to restore cognitive function. The ADDF has supported Dr. Brinton’s development of this therapy for over a decade. This grant supports the creation of a patentable formulation of allopregnanolone. This will allow Dr. Brinton to commercialize her therapy if future clinical trials are successful. The funding was awarded as part of Dr. Brinton’s receipt of the 2017 Goodes Prize for Excellence in Alzheimer’s Drug Discovery.

Page 1 of 58